Abstract: Glucocorticoid-induced osteoporosis is a clinical problem in patients under chronic steroid therapy. To delineate the action of glucocorticoids on osteoblasts, we performed microarray analysis using rat primary osteoblasts and identified several glucocorticoid target genes. We validated the dexamethasone-induced upregulation of CCAAT/ enhancer-binding protein delta (C/EBP ), endothelial PAS-domain protein 1 (EPAS1), matrix Gla protein (MGP), and nerve growth factor inducible-B (NGFI-B) expression by quantitative real time-polymerase chain reaction (qPCR). EPAS1 overexpression inhibited, whereas dominant-negative EPAS1 overexpression enhanced the upregulation of osteoblastic marker genes and the mineralization in ST2 mesenchymal cells under the simulated osteoblastogenesis conditions. These results suggest that glucocorticoids could inhibit osteoblastic differentiation by regulating its target genes, as exemplified by EPAS1.
INTRODUCTION
Glucocorticoids (GC), which are widely used as antiinflammatory and immunosuppressive agents, have serious side effects on bones, causing bone loss and osteoporosis [1, 2] . GC-induced bone loss has also been reported in mice [3] and rat [4] , suggesting that GC exerts common bone-tissue effects among mammalian species. Furthermore, GC is known to play a stimulatory role in bone resorption; thus, these steroids would also have detrimental effects on osteoblast proliferation, differentiation, and physiological function [1] . GC may impair osteoblastic metabolism by inhibiting collagen synthesis and the functions of osteoblastogenesis-related genes, including core binding factor 1 (Cbfa1), insulin-like growth factor (IGF)-1, and transforming growth factor (TGF)- [5] [6] [7] . GC also induces apoptosis of osteoblasts [3, 8] .
The intensity of the GC effects depends on the growth and differentiation stages of osteoblasts [9, 10] as well as the concentration of glucocorticoid [11] . For example, cortisol has been shown to prevent the terminal differentiation of primary osteoblasts during osteoblastic differentiation and mineralization [10] . Dexamethasone (Dex) inhibited cell cycle progression and mineralization in MC3T3-E1 osteoblastic cells in postconfluent cultures, but not in preconfluent cultures [9] .
*Address correspondence to this author at the Department of Geriatric Medicine, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan; Tel: +81-3-5800-8652; Fax: +81-42-984-4541; E-mail: INOUE-GER@h.u-tokyo.ac.jp GC regulates the transcription of its target genes and exerts various biological functions by binding to the glucocorticoid receptor (GR), one of the classical steroid hormone nuclear receptors. GR expression has also been confirmed in osteoblasts, where GC regulates the expression of several target genes, including bone sialoprotein [12] , glutamine synthase [13] , and dickkopf-1 [14] . However, the identification of additional target genes is essential to understand the precise mechanism underlying GC-induced osteoporosis. In the present study, we examined GC-regulated gene expression in rat primary osteoblasts at different differentiation stages and identified novel GC target genes that contribute to osteoblastic differentiation in differentiation stage-specific and GC dose-dependent manners.
MATERIALS AND METHODOLOGY

Cell Culture
Rat primary osteoblasts were isolated from the calvaria of 5-day-old neonatal rats as described previously [15] . Cells obtained from the second passage were used for experiments. All animal experiments were approved by the Institutional Animal Care and Use Committee. ST2 cells were obtained from American Type Culture Collection (Manassas, VA), and maintained in alpha-minimum essential medium ( -MEM) supplemented with 10% fetal bovine serum (FBS), 50 units/ml penicillin, and 50 μg/ml streptomycin.
Induction of Osteoblastic Differentiation
Rat primary osteoblasts were maintained in culture medium containing -MEM (including 50 μg/ml ascorbic acid) with 10% FBS and antibiotics. After 1 week of culture, when a confluent cell layer was obtained, the culture medium was replaced with osteoblast differentiation medium containing -MEM with 50 nM -glycerophosphate, and the cells were then cultured for another 1 or 3 weeks (hereafter, mentioned as 2 and 4 weeks of culture, respectively). Increased mRNA levels of the differentiation markers alkaline phosphatase (ALP) and osteocalcin were confirmed by real-time polymerase chain reaction (PCR) during the 4-week differentiation course; this was consistent with previous reports [1] . Thus, the model used in the present study reflects the differentiation process of osteoblastic cells. The culture medium was changed 24 h before every analysis. ST2 cells were grown to confluency, and differentiation was induced at 1 d postconfluence (day 0) by replacing the culture medium with the differentiation medium, i.e., medium containing 20 ng/ml bone morphogenetic protein 9 (BMP-9) (R&D systems, Minneapolis, MN). The differentiation medium was also changed every 3 d, and the cells were cultured up to 9 d after differentiation was induced (day 9).
Microarray Analysis
At 2 and 4 weeks of culture, the cells were incubated with 10 nM Dex or a vehicle for 2 or 6 h, and then, total RNA was extracted from the cells using a ToTALLY RNA Kit (Ambion, Austin, TX). cDNA was synthesized from 5 μg of total RNA using a T7 promoter primer and amplified to generate cyanine 3-or cyanine 5-labeled cRNA using the Fluorescent Linear Amplification Kit (Agilent Technology, Palo Alto, CA). cDNA derived from Dex-treated primary osteoblasts and vehicle-treated primary osteoblasts were labeled with cyanine 5 and cyanine 3, respectively. Hybridization solution was prepared, subjected to the rat oligomicroarray (Agilent Technology), and hybridized at 60°C for 17 h. After hybridization, the microarray was scanned with the GenePix 4000B scanner (Molecular Devices, Union City, CA). The raw data obtained from the scanned array images were analyzed with the Genespring 6.1 software (Agilent Technology). In the present study, if the expression of a gene increased by greater than 2.5 fold at either 2 or 6 h after Dex treatment compared with the vehicle treatment, it was considered to be upregulated.
Plasmid Construction
Human endothelial PAS-domain protein 1 (EPAS1) cDNA (EPAS1 amino acids 2-870) or its dominant-negative mutant (EPAS1 amino acids 2-485) were N-terminally tagged with Flag and HA, and subcloned into the pCXN2 vector (pCXN2-FLAG-HA-EPAS1 and pCXN2-FLAG-HA-DN-EPAS1, respectively).
Quantitative Real Time-PCR
Total RNA was extracted from rat primary osteoblasts or ST2 cells at the indicated times during the period of osteoblastic induction. Quantitative real time-PCR (qPCR) analysis was performed as described previously [16] . The sequences of the PCR primers for glyceraldehyde-3-phosphate dehydrogenase (GAPDH), ALP, osteocalcin, CCAAT/ enhancer-binding protein delta (C/EBP ), EPAS1, matrix Gla protein (MGP), and nerve growth factor inducible-B (NGFI-B) for rat and GAPDH, ALP, and osteocalcin for mouse are listed in Table 1 .
The expression level of each gene was normalized to the GAPDH expression level. Three independent measurements were performed and the standard error was calculated.
Generation of Stable Cell Lines
ST2 cells were transfected with pCXN2-FLAG-HA-EPAS1, pCXN2-FLAG-HA-DN-EPAS1 or empty pCXN2 plasmid using the Lipofectamine 2000 reagent (Invitrogen, Carlsbad, CA) and neo-resistant clones were isolated by G418 selection (0.6 mg/ml). Expression levels of FLAG-HA-human EPAS1 or FLAG-HA-human DN-EPAS1 mRNA were measured by qPCR using the following von Kossa Staining ST2 cells stably expressing EPAS1 (ST2-EPAS1) or a dominant negative EPAS1mutant (ST2-DN-EPAS1) were cultured in an osteoblast differentiation medium for 30 d; thereafter, von Kossa staining for calcium was performed as described previously [17] . Briefly, fixed cells were incubated with 5% silver nitrate for 5 min in daylight. All the staining images were captured and the intensity of staining was quantified using the NIH Image program (developed at the U.S. National Institutes of Health and available on the internet at http://rsb.info.nih.gov/nih-image/). The results were indicated as the mean ± SD of the relative intensity of 10 independent areas in each cell culture.
Statistical Analysis
Differences between the 2 groups were analyzed using the paired Student's t test. A p value less than 0.05 was considered to be significant. All data are presented in the text and figures as the mean ± SD.
RESULTS
Microarray Analysis of Rat Primary Osteoblasts Treated with Dex after Osteoblastic Differentiation
We performed microarray analysis using mRNA obtained from rat primary osteoblasts at 2 and 4 weeks after osteoblastic differentiation, i.e., "early and late differentiation stages," respectively, to identify genes that were upregulated by Dex treatment. Cells at 2 weeks after differentiation were cultured for a week to obtain a confluent cell layer and for another week with -glycerophosphate, while cells at 4 weeks were cultured for 2 more weeks withglycerophosphate. Note that the calcification of primary osteoblasts was observed only at a "late differentiation stage." The primary osteoblasts at the early and late differentiation stages were treated with Dex (10 nM) for 2 h or 6 h, and genes that were upregulated by >2.5 fold in response to Dex treatment were defined as GC target genes.
At the early and late differentiation stages, 18 and 50 genes were upregulated by Dex treatment, respectively (Tables 2 and 3). Sixteen genes were upregulated at both stages. Other genes may be induced stage specifically. In contrast, 6 and 8 genes were down-regulated by Dex treatment at early and late differentiation stages, respectively (Tables 4 and 5). Three genes were down-regulated at both stages.
Validation of Dex-Induced Up-Regulated Genes Identified in Microarray Analysis
Among Dex-induced upregulated genes in primary osteoblasts, we were interested in genes that could be related to mesenchymal cell differentiation and bone metabolism. On the basis of these criteria, we identified 4 genes, including C/EBP , EPAS1, MGP, and NGFI-B. C/EBP is known as a transcriptional activator of adipogenesis similar to other C/EBP family members [18] . EPAS1 is a transcription factor that is also reported to play a role in adipogenic differentiation of 3T3-L1 preadipocytes [19] . MGP is known as a modulator of calcification in osteoblasts [20] .
The NR4A family, including NGFI-B, has been shown to regulate osteoblastic gene expression [21, 22] .
To validate GC-dependent expression of these 4 genes in primary osteoblasts, we performed qPCR using rat primary osteoblasts at early and late differentiation stages treated with 2 different doses of Dex (10 nM and 1 μM) (Fig. 1) . The upregulated profile of C/EBP , EPAS1, and MGP mRNA in primary osteoblasts was almost identical at both differentiation periods and at both Dex concentrations. In contrast, the NGFI-B mRNA expression pattern appeared to vary on the basis of the differentiation stage and GC dose. In primary osteoblasts 2 weeks after osteoblastic differentiation, NGFI-B mRNA was not induced by the treatment with either Dex dose. In primary osteoblasts 4 weeks after differentiation, NGFI-B mRNA was induced by both Dex doses; upregulation was observed at 2 h after low-dose treatment and 6 h after the high-dose treatment.
( 
Stable Expression of EPAS1 Attenuates Induction of Osteoblast Marker Genes during Osteoblastic Differentiation
Next, we particularly interested in EPAS1 because its remarkable GC-dependent up-regulation was shown at both early and late stage of osteoblastic differentiation, nevertheless, its transcriptional regulatory role in bone has not been well clarified in contrast to its possible promoting function in adipocytic differentiation, as reported in a study using 3T3-L1 preadipocytes [19] . We therefore would like to elucidate whether EPAS1 is a critical transcription factor that modulates osteoblastic differentiation in response to GC treatment. To further characterize the function of EPAS1 during osteoblastic differentiation, we used an in vitro differentiation model of ST2 mouse mesenchymal cells that stably expressed EPAS1 because rat primary osteoblasts were considered to be unsuitable for stable expression of plasmid DNA and appropriate rat-derived undifferentiated osteoblastic cells were not available. It is known that ST2 cells are multipotent and can differentiate into both osteoblast and adipocyte lineages in vitro [23] . We generated ST2 clones that stably expressed human EPAS1 (1-870 amino acids, ST2-EPAS1 cells), a dominant negative mutant of EPAS1 containing the N-terminal domain but lacking the transcriptional activation domain (1-485 amino acids, ST2-DN-EPAS1 cells) [24] or the empty vector (ST2-vector cells). Exogenous expression of EPAS1 or DN-EPAS1 was confirmed by qPCR in the ST2-EPAS1 clones E17 and E26 or the ST2-DN-EPAS1 clones D8 and D9, respectively, but not in the ST2-vector clones V1 and V2 ( Figs. 2A and B) . BMP-9, a recently identified osteoblastic inducer that is more potent than the well-known osteoblastic reagent BMP-2, was used to induce the differentiation of the ST2 clones into the osteoblast lineage [25, 26] . The expression of the osteoblast marker genes during the differentiation was investigated by qPCR. Overexpression of EPAS1 significantly attenuated the time-dependent induction of ALP and osteocalcin mRNA in ST2-EPAS1 clones on days 6 and 9 compared to the ST2-vector clones (Figs. 2C and D) .
Interestingly, ALP and osteocalcin expression was enhanced in the ST2-DN-EPAS1 clones compared with the control clones on days 6 and 9 (Figs. 2C and D) . To evaluate the effect of EPAS1 in mineralization, we performed von Kossa staining for these ST2 clones 30 d after the culture. The intensity of staining was significantly reduced in ST2-EPAS1 clones whereas it was enhanced in ST2-DN-EPAS1 clones compared with the ST2-vector clones (Fig. 2E) . Taken together, our functional study revealed that EPAS1 negatively modulates the expression of osteoblastic marker genes and functions as an inhibitory factor for osteoblastic differentiation.
DISCUSSION AND CONCLUSION
In the present study, we identified GC target genes in rat primary osteoblasts at the early and late stages of osteoblastic differentiation by microarray analysis. Among the Dex-induced upregulated genes, we confirmed by qPCR that C/EBP , EPAS1, and MGP expression was upregulated at both differentiation stages, whereas NGFI-B expression was upregulated only at the late differentiation stage. It is interesting that some of glucocorticoid-induced genes responded to the stimuli in GC dose-and differentiation stagespecific manners because this diversity of GC-induced gene regulation will be related to the various physiological effects of GC in different situations.
Among the GC target genes identified during osteoblastic differentiation, we showed that EPAS1 inhibits osteoblastic differentiation. The stable expression of EPAS1 in ST2 mesenchymal cells reduced the differentiation-dependent induction of osteoblastic marker gene expression, whereas dominant-negative EPAS1 expression substantially enhanced gene induction. EPAS1 is also a transcriptional factor that is shown to play a role in adipocyte differentiation in 3T3-L1 preadipocytic cells during adipogenesis induced by Dex [19] . Taken together, GC modulates mesenchymal cell differentiation by regulating the functions of critical transcriptional factors such as EPAS1. We identified the transcriptional factor C/EBP as a GC target in osteoblastic differentiation. It has been also shown that C/EBP contributes to adipogenesis like other the CCAAT/enhancer binding protein family members C/EBP Rat primary osteoblasts were cultured for 2 (A) or 4 (B) weeks, and treated with 10 nM or 1 μM Dex. Before and after 2 or 6 h of treatment, RNA was extracted and the expression levels of the indicated genes were analyzed. The values were normalized to those for GAPDH and shown as the fold change over the mRNA level at 0 h. Each result is the mean ± SD of 3 independent experiments. The microarray expression values of rat primary osteoblasts treated with 10 nM Dex were shown below of each graph, except NGFI-B data at the time after 2-week culture of osteoblastic differentiation.
and C/EBP [18, 27] . In primary osteoblasts, C/EBP is reported to play a role in GC-dependent transcriptional repression of insulin-like growth factor (IGF)-I [28] . Since IGF-I is a known regulator of bone acquisition and maintenance [29] , our results of GC-dependent C/EBP upregulation in osteoblastic differentiation suggest that GC represses some essential osteoblastic signals, such as IGF-I, via C/EBPdependent transcriptional regulation.
GC-dependent upregulation of MGP is another critical factor that contributes to the suppression of osteoblastic differentiation and bone acquisition. MGP is one of the noncollagenous bone matrix proteins. In addition to our findings, GC-dependent MGP upregulation has also been reported in rat lung cells [30] . A previous study of MGP knockout mice suggests that MGP is an inhibitor of bone mineralization, as MGP-deficient mice exhibit inappropriate calcification of various cartilages and ectopic vascular calcification [20] . Therefore, GC-dependent upregulation of MGP could also play a role in the inhibition of bone formation by suppressing mineralization in vivo.
Compared with other GC target genes that we focused on in the present study, the NGFI-B mRNA expression pattern seems to vary on the basis of the differentiation stage and Dex concentration. NGFI-B, also known as Nur77 or TR3, is a nuclear orphan receptor that belongs to the NR4A subfamily [31] . NGFI-B expression is induced by phytohemagglutinin in human lymphocytes and by serum stimulation of arrested fibroblasts [32] . Translocation of the NGFI-B protein from the nucleus to mitochondria induces apoptosis [33] . Regarding the relationship between NR4A and bone formation, the NR4A family has been shown to regulate osteoblastic gene expression [34] . Our RT-PCR results show that the regulation of NGFI-B expression by Dex in primary osteoblasts was dependent on both the dose and differentiation stage. These results were consistent with the microarray data as NGBI-B mRNA was found to be upregulated in a Dex-dependent manner only in primary osteoblasts at 4 weeks after osteoblastic differentiation. However, we could not rule out the possibility that NGFI-B expression may be up-regulated within 2 h, therefore, it is necessary to examine whether the acute change of NGFI-B expression may occur. On the other hand, C/EBP , EPAS1, and MGP were found to be upregulated in a Dex-dependent manner in primary osteoblasts at both differentiation stages, suggesting that some of glucocorticoid-induced genes respond to the stimuli in GC dose-and differentiation stage-specific manners.
In conclusion, we revealed in the present study that C/EBP , EPAS1, MGP, and NGFI-B were upregulated by Dex. EPAS1 overexpression inhibited, while dominant-negative EPAS1 overexpression enhanced the upregulation of osteoblastic marker genes and the mineralization in ST2 mesenchymal cells during osteoblastogenesis. We propose that glucocorticoids inhibit osteoblastic differentiation by regulating target genes such as EPAS1. 
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